Rpo LLC Takes $55,000 Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Rpo LLC purchased a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 17,969 shares of the biopharmaceutical company’s stock, valued at approximately $55,000.

A number of other large investors have also bought and sold shares of RVNC. Charles Schwab Investment Management Inc. raised its stake in shares of Revance Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company’s stock valued at $2,424,000 after acquiring an additional 6,462 shares during the last quarter. Rhumbline Advisers raised its position in Revance Therapeutics by 5.1% during the 4th quarter. Rhumbline Advisers now owns 142,603 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 6,885 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Revance Therapeutics by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 2,297,582 shares of the biopharmaceutical company’s stock worth $6,986,000 after buying an additional 7,928 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Revance Therapeutics in the 3rd quarter worth approximately $88,000. Finally, Virtu Financial LLC purchased a new position in shares of Revance Therapeutics during the third quarter valued at approximately $120,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Stock Performance

Shares of RVNC opened at $3.65 on Thursday. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $6.65. The firm’s 50-day simple moving average is $3.65 and its two-hundred day simple moving average is $4.08. The stock has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Analyst Ratings Changes

A number of brokerages recently commented on RVNC. StockNews.com assumed coverage on Revance Therapeutics in a research note on Thursday. They issued a “hold” rating for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Mizuho reduced their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Finally, Barclays lowered their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.